Foundation Medicine were yestoday granted US Patent 9,340,830 “Optimization of Multigene Analysis of Tumor Samples”. This is likely to stir up the can of worms that is tumour testing by NGS and is another patent in a complex landscape. The claims basically cover WGS library prep, exome sequencing, alignment and variant calling. It covers all sorts of mutation calling including SNVs at low freq (5%) and mid-freq (10%) or above, SNPs to assess CNV & LOH, fusions and other structural variants, as well as pharmacogenomic SNPs. It also includes in the test a DNA fingerprint.
Michael Pellini, Foundation’s CEO appears to be using some very positive language in describing the award of this patent, he said “we do not intend to block the use of methods covered by the patent in patient testing that may be offered by others”. But how much of the patent claim is truly novel and might stand up in court remains to be seen. The basic idea of exome sequencing patients is old hat and Foundation were certainly not the first people to be doing this. The SNP ID of patients is an idea even I’d proposed over four years ago (here & here). But if Foundation’s patent makes it harder for others to clamp down on competition that can only be a good thing.
Well that positive language was apparently BS. They just sued based on the patent: https://www.genomeweb.com/cancer/foundation-medicine-sues-guardant-health-patent-infringement
They will of course not block the use, but they will require a license :). I think the Guardant lawsuit does set a dangerous precedence – ironically – for them.
this will never hold up in court..
Great!
Happy New Year Quotes
Government Jobs
Banking Jobs
Railway Jobs
UPSC Recruitment
Defence Jobs
GPSC Recruitment
OPSC Recruitment
RPSC Recruitment
MPPSC Recruitment
HPPSC Recruitment
Govt Jobs
FIFA World Cup 2018
FIFA World Cup 2018 Schedule